BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1228 related articles for article (PubMed ID: 25014239)

  • 1. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
    Weinmann A; Sattler T; Unold HP; Grambihler A; Teufel A; Koch S; Schuchmann M; Biesterfeld S; Wörns MA; Galle PR; Schulze-Bergkamen H
    J Clin Gastroenterol; 2015; 49(5):438-47. PubMed ID: 25014239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
    Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid.
    Joshi S; Cauch-Dudek K; Wanless IR; Lindor KD; Jorgensen R; Batts K; Heathcote EJ
    Hepatology; 2002 Feb; 35(2):409-13. PubMed ID: 11826416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overlap of primary biliary cirrhosis and autoimmune hepatitis: Characteristics, therapy, and long term outcomes.
    Yokokawa J; Saito H; Kanno Y; Honma F; Monoe K; Sakamoto N; Abe K; Takahashi A; Yokokawa H; Ohira H
    J Gastroenterol Hepatol; 2010 Feb; 25(2):376-82. PubMed ID: 19817953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis.
    Efe C; Ozaslan E; Heurgué-Berlot A; Kav T; Masi C; Purnak T; Torgutalp M; Muratori L; Bresson-Hadni S; Thiéfin G; Schiano TD; Muratori P; Wahlin S
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):532-7. PubMed ID: 24614697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
    Corpechot C; Chazouillères O; Poupon R
    J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical features of 35 cases of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome].
    Zeng Z; Han YK; Zhang XF; Geng H
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):3-5. PubMed ID: 15670480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
    Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
    Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
    Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival.
    Al-Chalabi T; Portmann BC; Bernal W; McFarlane IG; Heneghan MA
    Aliment Pharmacol Ther; 2008 Jul; 28(2):209-20. PubMed ID: 18433467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
    Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
    J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis.
    Ozaslan E; Efe C; Heurgué-Berlot A; Kav T; Masi C; Purnak T; Muratori L; Ustündag Y; Bresson-Hadni S; Thiéfin G; Schiano TD; Wahlin S; Muratori P
    Clin Gastroenterol Hepatol; 2014 May; 12(5):863-9. PubMed ID: 24076417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overlap syndrome: autoimmune hepatitis with primary biliary cirrhosis.
    Arulprakash S; Sasi AD; Bala MR; Pugazhendhi T; Kumar SJ
    J Assoc Physicians India; 2010 Jul; 58():455-6. PubMed ID: 21121216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
    Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
    Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution from primary biliary cirrhosis to primary biliary cirrhosis/autoimmune hepatitis overlap syndrome.
    Twaddell WS; Lefkowitch J; Berk PD
    Semin Liver Dis; 2008 Feb; 28(1):128-34. PubMed ID: 18293283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
    Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
    Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of autoimmune hepatitis in primary biliary cirrhosis.
    Gossard AA; Lindor KD
    Liver Int; 2007 Oct; 27(8):1086-90. PubMed ID: 17845536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Bonder A; Retana A; Winston DM; Leung J; Kaplan MM
    Clin Gastroenterol Hepatol; 2011 Jul; 9(7):609-12. PubMed ID: 21440668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
    Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
    Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.